Michael Klichinsky - 01 Oct 2025 Form 4 Insider Report for Carisma Therapeutics Inc. (CARM)

Signature
/s/ Michael Klichinsky
Issuer symbol
CARM
Transactions as of
01 Oct 2025
Net transactions value
-$124,343
Form type
4
Filing time
03 Oct 2025, 17:25:16 UTC
Previous filing
30 Jan 2025
Next filing
08 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klichinsky Michael Chief Scientific Officer 3675 MARKET STREET, SUITE 401, PHILADELPHIA /s/ Michael Klichinsky 03 Oct 2025 0001967221

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARM Common Stock Sale $42,405 -165,000 -34% $0.2570 319,347 01 Oct 2025 Direct F1
transaction CARM Common Stock Sale $50,860 -200,000 -63% $0.2543 119,347 02 Oct 2025 Direct F2
transaction CARM Common Stock Sale $31,078 -119,347 -100% $0.2604 0 03 Oct 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2504 to $0.2721, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2501 to $0.2616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.2588 to $0.2670, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.